BACKGROUND: Recent evidence suggests that deep brain stimulation of the subthalamic nucleus (STN-DBS) may have a disease modifying effect in early Parkinson's disease (PD). A randomised, prospective study is underway to determine whether STN-DBS in early PD is safe and tolerable. OBJECTIVES/ METHODS:15 of 30 early PD patients were randomised to receive STN-DBS implants in an institutional review board approved protocol. Operative technique, location of DBS leads and perioperative adverse events are reported. Active contact used for stimulation in these patients was compared with 47 advanced PD patients undergoing an identical procedure by the same surgeon. RESULTS: 14 of the 15 patients did not sustain any long term (>3 months) complications from the surgery. One subject suffered a stroke resulting in mild cognitive changes and slight right arm and face weakness. The average optimal contact used in symptomatic treatment of early PD patients was: anterior -1.1±1.7 mm, lateral 10.7±1.7 mm and superior -3.3±2.5 mm (anterior and posterior commissure coordinates). This location is statistically no different (0.77 mm, p>0.05) than the optimal contact used in the treatment of 47 advanced PD patients. CONCLUSIONS: The perioperative adverse events in this trial of subjects with early stage PD are comparable with those reported for STN-DBS in advanced PD. The active contact position used in early PD is not significantly different from that used in late stage disease. This is the first report of the operative experience from a randomised, surgical versus best medical therapy trial for the early treatment of PD.
RCT Entities:
BACKGROUND: Recent evidence suggests that deep brain stimulation of the subthalamic nucleus (STN-DBS) may have a disease modifying effect in early Parkinson's disease (PD). A randomised, prospective study is underway to determine whether STN-DBS in early PD is safe and tolerable. OBJECTIVES/ METHODS: 15 of 30 early PDpatients were randomised to receive STN-DBS implants in an institutional review board approved protocol. Operative technique, location of DBS leads and perioperative adverse events are reported. Active contact used for stimulation in these patients was compared with 47 advanced PDpatients undergoing an identical procedure by the same surgeon. RESULTS: 14 of the 15 patients did not sustain any long term (>3 months) complications from the surgery. One subject suffered a stroke resulting in mild cognitive changes and slight right arm and face weakness. The average optimal contact used in symptomatic treatment of early PDpatients was: anterior -1.1±1.7 mm, lateral 10.7±1.7 mm and superior -3.3±2.5 mm (anterior and posterior commissure coordinates). This location is statistically no different (0.77 mm, p>0.05) than the optimal contact used in the treatment of 47 advanced PDpatients. CONCLUSIONS: The perioperative adverse events in this trial of subjects with early stage PD are comparable with those reported for STN-DBS in advanced PD. The active contact position used in early PD is not significantly different from that used in late stage disease. This is the first report of the operative experience from a randomised, surgical versus best medical therapy trial for the early treatment of PD.
Authors: Srivatsan Pallavaram; Pierre-Francois D'Haese; Chris Kao; Hong Yu; Michael Remple; Joseph Neimat; Peter Konrad; Benoit Dawant Journal: Med Image Comput Comput Assist Interv Date: 2008
Authors: Bradley A Wallace; Keyoumars Ashkan; Claire E Heise; Kelly D Foote; Napoleon Torres; John Mitrofanis; Alim-Louis Benabid Journal: Brain Date: 2007-06-20 Impact factor: 13.501
Authors: Paul Krack; Alina Batir; Nadège Van Blercom; Stephan Chabardes; Valérie Fraix; Claire Ardouin; Adnan Koudsie; Patricia Dowsey Limousin; Abdelhamid Benazzouz; Jean François LeBas; Alim-Louis Benabid; Pierre Pollak Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245
Authors: Kurt G Schilling; Yurui Gao; Iwona Stepniewska; Vaibhav Janve; Bennett A Landman; Adam W Anderson Journal: Magn Reson Imaging Date: 2018-09-10 Impact factor: 2.546
Authors: David Charles; Peter E Konrad; Joseph S Neimat; Anna L Molinari; Michael G Tramontana; Stuart G Finder; Chandler E Gill; Mark J Bliton; Chris Kao; Fenna T Phibbs; Peter Hedera; Ronald M Salomon; Kevin R Cannard; Lily Wang; Yanna Song; Thomas L Davis Journal: Parkinsonism Relat Disord Date: 2014-03-28 Impact factor: 4.891
Authors: Andrew J Plassard; Shunxing Bao; Pierre F D'Haese; Srivatsan Pallavaram; Daniel O Claassen; Benoit M Dawant; Bennett A Landman Journal: Magn Reson Imaging Date: 2019-05-21 Impact factor: 2.546
Authors: Jonathan Matthew Cayce; Matthew B Bouchard; Mykyta M Chernov; Brenda R Chen; Lauren E Grosberg; E Duco Jansen; Elizabeth M C Hillman; Anita Mahadevan-Jansen Journal: Cell Calcium Date: 2014-01-31 Impact factor: 6.817
Authors: Andrew J Plassard; Pierre F D'Haese; Srivatsan Pallavaram; Allen T Newton; Daniel O Claassen; Benoit M Dawant; Bennett A Landman Journal: Proc SPIE Int Soc Opt Eng Date: 2017-02-24
Authors: Jutta S Mayer; Joseph Neimat; Bradley S Folley; Sarah K Bourne; Peter E Konrad; David Charles; Sohee Park Journal: Neurocase Date: 2016-06-23 Impact factor: 0.881
Authors: David Charles; Christopher Tolleson; Thomas L Davis; Chandler E Gill; Anna L Molinari; Mark J Bliton; Michael G Tramontana; Ronald M Salomon; Chris Kao; Lily Wang; Peter Hedera; Fenna T Phibbs; Joseph S Neimat; Peter E Konrad Journal: J Parkinsons Dis Date: 2012 Impact factor: 5.568
Authors: Sarah K B Bick; Bradley S Folley; Jutta S Mayer; Sohee Park; P David Charles; Corrie R Camalier; Srivatsan Pallavaram; Peter E Konrad; Joseph S Neimat Journal: Neuromodulation Date: 2016-10-12